 - For Phase 2 only, have had disease progression or be refractory or intolerant to 1 prior line of therapy first line therapy for recurrent or refractory for NSCLC or HCC and have refused currently approved second-line therapy. First line therapy is defined as therapy used to treat advanced disease. This may include multiple chemotherapeutic, targeted or immunotherapeutic agents with or without radiation therapy andor surgery. Each subsequent line of therapy is preceded by disease progression. A switch of an agent within the same drug class eg, cisplatinum to carboplatinum within a regimen in order to manage toxicity does not define the start of a new line of therapy. 